Arestat™ Protein Stabilisation Technology
Arestat™ comprises two fundamentally different aspects of our platform stabilisation technology – Arestat-T™ and Arestat-R™. Both utilise excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability.
Both are available for licensing for therapeutic proteins, vaccines, medial devices and diagnostics.
High Concentrations of Biopharmaceuticals
Therapeutic antibodies have made an important contribution to modern medicine and drug development pipelines reflect this. However, due to the requirement of a high therapeutic dose, many antibodies are administered by slow intravenous infusion (that can take as long as four hours, in the case of rituximab), in a hospital clinic setting. This is not only inconvenient for patients but limits administration to clinical settings which can be costly.
A number of pharmaceutical and biotechnology companies are presently seeking novel ways of increasing the therapeutic dose for their proprietary antibodies to levels as high as 200 mg/ml. Through the application of Arestat™ technologies, Arecor has demonstrated that higher concentrations of proteins can be maintained in storage without degradation or aggregation typically associated with such formulations. Arecor is working with a range of approved recombinant therapeutic proteins at significantly higher doses than the marketed brands thereby creating opportunities for new routes of administration for these formulations.